8NN Stock Overview

Produces and supplies alpha-particle emitters for cancer therapy in Norway. More details

8NN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (NOK0)

Does not have a meaningful market cap (€819M)

Volatile share price over the past 3 months compared to the German market

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Thor Medical ASA Competitors

2invest

XTRA:2INV

€70.0m

4SC

DB:VSC

€40.4m

Heidelberg Pharma

XTRA:HPHA

€150.5m

Formycon

XTRA:FYB

€404.3m

Price History & Performance

Summary of share price highs, lows and changes for Thor Medical
Historical stock prices
Current Share Price	NOK 0.21
52 Week High	NOK 0.40
52 Week Low	NOK 0.076
Beta	0
1 Month Change	3.77%
3 Month Change	5.90%
1 Year Change	165.08%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	22.33%

Recent updates

Shareholder Returns

	8NN	DE Biotechs	DE Market
7D	4.5%	-0.3%	0.8%
1Y	165.1%	-12.7%	14.6%

Return vs Industry: 8NN exceeded the German Biotechs industry which returned -12.3% over the past year.

Return vs Market: 8NN exceeded the German Market which returned 14.6% over the past year.

Price Volatility

Is 8NN's price volatile compared to industry and market?
8NN volatility
8NN Average Weekly Movement	10.2%
Biotechs Industry Average Movement	5.7%
Market Average Movement	6.6%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: 8NN's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 8NN's weekly volatility has decreased from 21% to 10% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2009	9	Jasper Kurth	www.thormedical.no

Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was incorporated in 2009 and is headquartered in Oslo, Norway.

Thor Medical ASA Fundamentals Summary

How do Thor Medical's earnings and revenue compare to its market cap?
8NN fundamental statistics
Market cap	€70.64m
Earnings (TTM)	-€3.64m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-19.4x

P/E Ratio

Is 8NN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8NN income statement (TTM)
Revenue	NOK 0
Cost of Revenue	NOK 0
Gross Profit	NOK 0
Other Expenses	NOK 42.21m
Earnings	-NOK 42.21m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Aug 29, 2025

Earnings per share (EPS)	-0.13
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 8NN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/18 14:18
End of Day Share Price	2025/05/16 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Thor Medical ASA is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.